 Sarah Billups
Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 17 | 2023 | 231 | 3.320 |
Why?
| | Osteoporosis | 4 | 2023 | 224 | 2.420 |
Why?
| | Osteoporotic Fractures | 3 | 2023 | 54 | 1.730 |
Why?
| | Bone Density Conservation Agents | 4 | 2022 | 62 | 1.700 |
Why?
| | Osteoporosis, Postmenopausal | 3 | 2022 | 36 | 1.270 |
Why?
| | Hypertension | 7 | 2023 | 1052 | 1.060 |
Why?
| | Pharmaceutical Services | 7 | 2020 | 76 | 1.050 |
Why?
| | Primary Health Care | 10 | 2023 | 1502 | 0.930 |
Why?
| | Pharmacy Service, Hospital | 11 | 2017 | 83 | 0.830 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 131 | 0.790 |
Why?
| | Communicable Diseases | 1 | 2023 | 127 | 0.760 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 179 | 0.730 |
Why?
| | Blood Pressure Determination | 2 | 2018 | 122 | 0.680 |
Why?
| | Emergency Service, Hospital | 5 | 2023 | 1815 | 0.680 |
Why?
| | Patient Transfer | 1 | 2020 | 142 | 0.600 |
Why?
| | Diphosphonates | 2 | 2015 | 51 | 0.590 |
Why?
| | Medication Adherence | 4 | 2015 | 531 | 0.560 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 663 | 0.560 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2016 | 18 | 0.560 |
Why?
| | Retrospective Studies | 19 | 2023 | 12521 | 0.560 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2014 | 61 | 0.550 |
Why?
| | Pharmacy Residencies | 1 | 2016 | 11 | 0.530 |
Why?
| | Quality Improvement | 1 | 2023 | 944 | 0.530 |
Why?
| | Community Pharmacy Services | 2 | 2013 | 42 | 0.520 |
Why?
| | Research | 2 | 2016 | 389 | 0.510 |
Why?
| | Aged | 31 | 2023 | 18973 | 0.510 |
Why?
| | Telephone | 1 | 2015 | 152 | 0.450 |
Why?
| | Hospitals, Veterans | 9 | 2001 | 244 | 0.440 |
Why?
| | Patient Satisfaction | 5 | 2013 | 571 | 0.440 |
Why?
| | Pharmacies | 1 | 2014 | 32 | 0.430 |
Why?
| | Patient Compliance | 5 | 2009 | 524 | 0.430 |
Why?
| | Correspondence as Topic | 2 | 2015 | 14 | 0.420 |
Why?
| | Humans | 52 | 2023 | 114075 | 0.410 |
Why?
| | Health Maintenance Organizations | 4 | 2014 | 93 | 0.400 |
Why?
| | Aged, 80 and over | 9 | 2023 | 6307 | 0.400 |
Why?
| | Professional Role | 5 | 2020 | 148 | 0.390 |
Why?
| | Cohort Studies | 9 | 2023 | 4884 | 0.390 |
Why?
| | Delivery of Health Care, Integrated | 5 | 2018 | 227 | 0.390 |
Why?
| | Insurance, Health | 1 | 2014 | 243 | 0.380 |
Why?
| | Prescription Drugs | 1 | 2013 | 116 | 0.380 |
Why?
| | Female | 39 | 2023 | 59346 | 0.370 |
Why?
| | Cost Savings | 2 | 2015 | 74 | 0.360 |
Why?
| | Neuromuscular Agents | 1 | 2011 | 30 | 0.350 |
Why?
| | Drug Prescriptions | 4 | 2020 | 237 | 0.340 |
Why?
| | Drug Therapy | 2 | 2000 | 74 | 0.330 |
Why?
| | Drug Monitoring | 6 | 2014 | 184 | 0.330 |
Why?
| | HIV Infections | 1 | 2023 | 2453 | 0.320 |
Why?
| | Nortriptyline | 1 | 2009 | 5 | 0.320 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2009 | 2 | 0.320 |
Why?
| | Middle Aged | 23 | 2023 | 26620 | 0.320 |
Why?
| | Amitriptyline | 1 | 2009 | 20 | 0.320 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 28 | 0.320 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 38 | 0.310 |
Why?
| | Perception | 2 | 2023 | 309 | 0.310 |
Why?
| | Male | 35 | 2023 | 55416 | 0.300 |
Why?
| | Tetrahydronaphthalenes | 2 | 1998 | 29 | 0.300 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1168 | 0.300 |
Why?
| | Calcium Channel Blockers | 2 | 1998 | 113 | 0.290 |
Why?
| | Antihypertensive Agents | 4 | 2023 | 428 | 0.290 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1175 | 0.290 |
Why?
| | Benzimidazoles | 2 | 1998 | 137 | 0.280 |
Why?
| | Pilot Projects | 2 | 2023 | 1361 | 0.280 |
Why?
| | Fractures, Bone | 1 | 2012 | 367 | 0.270 |
Why?
| | Managed Care Programs | 2 | 2013 | 133 | 0.260 |
Why?
| | American Heart Association | 2 | 2020 | 264 | 0.250 |
Why?
| | Colorado | 8 | 2017 | 4092 | 0.250 |
Why?
| | Adult | 15 | 2023 | 30394 | 0.250 |
Why?
| | Lovastatin | 1 | 2005 | 26 | 0.250 |
Why?
| | Simvastatin | 1 | 2005 | 58 | 0.250 |
Why?
| | Patient Acceptance of Health Care | 2 | 2023 | 678 | 0.250 |
Why?
| | Ambulatory Care | 6 | 2010 | 480 | 0.240 |
Why?
| | Heart Diseases | 1 | 2008 | 329 | 0.230 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2018 | 239 | 0.230 |
Why?
| | Health Care Costs | 2 | 2014 | 381 | 0.230 |
Why?
| | Bone Density | 2 | 2022 | 432 | 0.230 |
Why?
| | Migraine Disorders | 2 | 2020 | 82 | 0.220 |
Why?
| | Wounds and Injuries | 1 | 2011 | 674 | 0.220 |
Why?
| | Cholesterol | 2 | 2020 | 368 | 0.220 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 224 | 0.210 |
Why?
| | Blood Pressure | 2 | 2023 | 1531 | 0.200 |
Why?
| | Denosumab | 1 | 2022 | 7 | 0.200 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1381 | 0.190 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 771 | 0.190 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 373 | 0.190 |
Why?
| | Diabetes Mellitus | 2 | 2013 | 898 | 0.190 |
Why?
| | Academic Medical Centers | 1 | 2023 | 405 | 0.180 |
Why?
| | Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 3 | 0.180 |
Why?
| | Young Adult | 5 | 2023 | 10458 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2023 | 632 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2023 | 526 | 0.160 |
Why?
| | Student Health Services | 1 | 2018 | 15 | 0.150 |
Why?
| | Electronic Health Records | 3 | 2022 | 801 | 0.150 |
Why?
| | Antimanic Agents | 1 | 2018 | 14 | 0.150 |
Why?
| | Lithium Compounds | 1 | 2018 | 9 | 0.150 |
Why?
| | Angina Pectoris | 1 | 1998 | 63 | 0.150 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1998 | 63 | 0.150 |
Why?
| | Drug Approval | 1 | 1998 | 78 | 0.150 |
Why?
| | Preceptorship | 1 | 2018 | 62 | 0.150 |
Why?
| | Guideline Adherence | 3 | 2020 | 489 | 0.150 |
Why?
| | Antidepressive Agents | 2 | 2017 | 195 | 0.150 |
Why?
| | Quality of Life | 4 | 2001 | 2344 | 0.140 |
Why?
| | Data Collection | 4 | 2014 | 618 | 0.140 |
Why?
| | Students, Pharmacy | 1 | 2018 | 97 | 0.140 |
Why?
| | Drug Interactions | 4 | 2012 | 337 | 0.140 |
Why?
| | Administration, Oral | 2 | 2015 | 725 | 0.130 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 183 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 248 | 0.120 |
Why?
| | Pharmaceutical Preparations | 2 | 2016 | 164 | 0.120 |
Why?
| | United States Department of Veterans Affairs | 5 | 2001 | 561 | 0.120 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 16 | 0.120 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 544 | 0.120 |
Why?
| | Patient Readmission | 1 | 2020 | 607 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2013 | 4392 | 0.120 |
Why?
| | Hematinics | 1 | 2014 | 18 | 0.120 |
Why?
| | Renal Insufficiency | 2 | 2015 | 137 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1472 | 0.120 |
Why?
| | Educational Measurement | 1 | 2016 | 235 | 0.110 |
Why?
| | United States | 13 | 2020 | 12143 | 0.110 |
Why?
| | Patient Discharge | 1 | 2020 | 770 | 0.110 |
Why?
| | Lipids | 1 | 2017 | 564 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 175 | 0.110 |
Why?
| | Adolescent | 4 | 2023 | 17810 | 0.110 |
Why?
| | Reminder Systems | 1 | 2015 | 159 | 0.110 |
Why?
| | Outpatients | 1 | 2016 | 325 | 0.110 |
Why?
| | Hospitalization | 2 | 2018 | 1762 | 0.100 |
Why?
| | Anemia | 1 | 2014 | 143 | 0.100 |
Why?
| | Colchicine | 1 | 2012 | 24 | 0.100 |
Why?
| | Gout Suppressants | 1 | 2012 | 20 | 0.100 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 64 | 0.100 |
Why?
| | Gout | 1 | 2012 | 36 | 0.100 |
Why?
| | Health Expenditures | 1 | 2014 | 172 | 0.100 |
Why?
| | Hematologic Diseases | 1 | 2012 | 55 | 0.100 |
Why?
| | Job Satisfaction | 1 | 2013 | 168 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 230 | 0.100 |
Why?
| | Drug Therapy, Combination | 2 | 2009 | 949 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2087 | 0.090 |
Why?
| | Hyperlipidemias | 3 | 2017 | 121 | 0.090 |
Why?
| | Depression | 2 | 2017 | 1133 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 125 | 0.090 |
Why?
| | Chronic Disease | 4 | 2008 | 1578 | 0.090 |
Why?
| | Evaluation Studies as Topic | 1 | 2011 | 167 | 0.090 |
Why?
| | Anticoagulants | 1 | 2015 | 547 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2018 | 3007 | 0.090 |
Why?
| | Mental Disorders | 1 | 2018 | 889 | 0.090 |
Why?
| | Diazepam | 1 | 2010 | 26 | 0.090 |
Why?
| | Amiodarone | 1 | 2010 | 23 | 0.090 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 43 | 0.080 |
Why?
| | Ipratropium | 1 | 2009 | 6 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 1958 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1181 | 0.080 |
Why?
| | Telemedicine | 1 | 2017 | 666 | 0.080 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2010 | 106 | 0.080 |
Why?
| | Time Factors | 4 | 2013 | 6077 | 0.080 |
Why?
| | Paroxetine | 1 | 2009 | 7 | 0.080 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2009 | 24 | 0.080 |
Why?
| | Risk Factors | 8 | 2018 | 8612 | 0.080 |
Why?
| | Bupropion | 1 | 2009 | 39 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2014 | 4403 | 0.080 |
Why?
| | Fluoxetine | 1 | 2009 | 46 | 0.080 |
Why?
| | Internet | 1 | 2013 | 591 | 0.080 |
Why?
| | Mibefradil | 2 | 1998 | 5 | 0.080 |
Why?
| | Prospective Studies | 5 | 2015 | 6198 | 0.080 |
Why?
| | Blood Glucose | 1 | 2017 | 1827 | 0.080 |
Why?
| | Fees, Pharmaceutical | 1 | 2008 | 13 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2018 | 4598 | 0.070 |
Why?
| | Bronchodilator Agents | 1 | 2009 | 239 | 0.070 |
Why?
| | Tryptamines | 1 | 2006 | 3 | 0.070 |
Why?
| | Sumatriptan | 1 | 2006 | 6 | 0.070 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 27 | 0.070 |
Why?
| | Financing, Personal | 1 | 2005 | 24 | 0.060 |
Why?
| | Drugs, Generic | 1 | 2005 | 18 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 979 | 0.060 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 86 | 0.060 |
Why?
| | Triazoles | 1 | 2006 | 125 | 0.060 |
Why?
| | Incidence | 1 | 2011 | 2314 | 0.060 |
Why?
| | Drug Costs | 1 | 2005 | 92 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1837 | 0.060 |
Why?
| | Age Factors | 1 | 2011 | 2886 | 0.060 |
Why?
| | Patients | 1 | 2005 | 163 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 307 | 0.060 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 129 | 0.060 |
Why?
| | Sex Factors | 1 | 2009 | 1707 | 0.050 |
Why?
| | Medical Records Systems, Computerized | 2 | 2006 | 88 | 0.050 |
Why?
| | Medicaid | 2 | 2017 | 404 | 0.050 |
Why?
| | Patient Care Team | 2 | 2013 | 517 | 0.050 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 11 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 907 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2006 | 9049 | 0.050 |
Why?
| | Sodium | 1 | 2022 | 184 | 0.050 |
Why?
| | Economics, Pharmaceutical | 1 | 2000 | 10 | 0.040 |
Why?
| | Medication Systems, Hospital | 1 | 1999 | 8 | 0.040 |
Why?
| | Veterans | 2 | 2001 | 1248 | 0.040 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 212 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 26 | 0.040 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2014 | 486 | 0.040 |
Why?
| | Software | 2 | 1999 | 526 | 0.040 |
Why?
| | Community Health Centers | 1 | 2018 | 53 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 899 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1998 | 80 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2018 | 128 | 0.040 |
Why?
| | Counseling | 1 | 2000 | 342 | 0.030 |
Why?
| | Prescription Drug Misuse | 1 | 2017 | 38 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 21 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 84 | 0.030 |
Why?
| | Health Status | 1 | 2001 | 717 | 0.030 |
Why?
| | Logistic Models | 1 | 2000 | 1829 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2015 | 42 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2388 | 0.030 |
Why?
| | Epoetin Alfa | 1 | 2014 | 6 | 0.030 |
Why?
| | Warfarin | 1 | 2015 | 136 | 0.030 |
Why?
| | Pain Management | 1 | 2017 | 285 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 1998 | 926 | 0.030 |
Why?
| | Erythropoietin | 1 | 2014 | 72 | 0.030 |
Why?
| | Publishing | 1 | 2015 | 123 | 0.030 |
Why?
| | Drug Overdose | 1 | 2017 | 292 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 18 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 909 | 0.030 |
Why?
| | Recurrence | 1 | 2015 | 925 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2012 | 61 | 0.020 |
Why?
| | Specialization | 1 | 2013 | 112 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 88 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 492 | 0.020 |
Why?
| | Education, Pharmacy | 1 | 2013 | 121 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1228 | 0.020 |
Why?
| | Hemorrhage | 1 | 2015 | 600 | 0.020 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2010 | 3 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 413 | 0.020 |
Why?
| | Thyrotropin | 1 | 2010 | 100 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2010 | 141 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 1726 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 743 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2009 | 77 | 0.020 |
Why?
| | Data Interpretation, Statistical | 2 | 2001 | 318 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 223 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1447 | 0.020 |
Why?
| | Models, Econometric | 1 | 2008 | 34 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1791 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 471 | 0.020 |
Why?
| | Cardiology | 1 | 2010 | 260 | 0.020 |
Why?
| | Electrocardiography | 1 | 2010 | 561 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 164 | 0.020 |
Why?
| | Analgesics | 1 | 2008 | 156 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 2247 | 0.020 |
Why?
| | Prognosis | 1 | 2013 | 3315 | 0.020 |
Why?
| | Child, Preschool | 1 | 2017 | 9118 | 0.010 |
Why?
| | Pain | 1 | 2008 | 701 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 1999 | 2764 | 0.010 |
Why?
| | Total Quality Management | 1 | 2001 | 61 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2001 | 155 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 249 | 0.010 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 127 | 0.010 |
Why?
| | Quality-Adjusted Life Years | 1 | 2000 | 103 | 0.010 |
Why?
| | Treatment Refusal | 1 | 2000 | 85 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2001 | 208 | 0.010 |
Why?
| | Child | 1 | 2017 | 18407 | 0.010 |
Why?
| | Linear Models | 1 | 2001 | 768 | 0.010 |
Why?
| | Medical Records | 1 | 1999 | 153 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2001 | 285 | 0.010 |
Why?
| | Health Services Research | 1 | 2001 | 373 | 0.010 |
Why?
| | Attitude to Health | 1 | 2001 | 398 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2001 | 1204 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2000 | 666 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1690 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2540 | 0.010 |
Why?
|
|
Billups's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|